Predictive factors for survival of oligometastatic colorectal cancer treated with Stereotactic body radiation therapy

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Background and purpose: Colorectal cancer (CRC) represents one of the major leading causes of death from cancer. Aim of the present study was to analyze outcome of oligometastatic CRC patients treated with stereotactic body radiation therapy (SBRT), and to evaluate predictive factors of survival. Materials and methods: We included patients with maximum 5 metastases. Previous/concomitant systemic treatments were allowed. End points of the present study were the outcome in terms of Local control of treated metastases (LC), progression free survival (PFS), and overall survival (OS). Results: 437 metastases were treated in 270 patients. Lung was site of metastases in 48.5% of cases, followed by liver (36.4%). Systemic treatment was administered before SBRT in 199 patients (73.7%). Median follow-up time was 23 months (3–98.7). Rates of LC at 1, 3 and 5 years were 95%, 73% and 73%, respectively. Time from diagnosis of metastases to SBRT was the only factor predictive of LC (HR 1.62, p = 0.023). Median PFS was 8.6 months. Rates of OS at 1, 3 and 5 years were 88.5%, 56.6%, and 37.2%, respectively. Lesion greater than 30 mm (HR 1.82, p = 0.030), presence of non-lung metastases (HR 1.67, p = 0.020), the use of systemic treatment before SBRT (HR 1.82, p = 0.023), and progression of treated metastases (HR 1.80, p = 0.007), were all predictive of worse OS. Conclusions: Stereotactic body radiation therapy represents an effective approach in the management of oligometastatic CRC. Control of treated oligometastases seems to be a strong positive predictive factor for both PFS and OS.

Original languageEnglish
JournalRadiotherapy and Oncology
DOIs
Publication statusAccepted/In press - Jan 1 2018

Fingerprint

Colorectal Neoplasms
Radiotherapy
Neoplasm Metastasis
Survival
Disease-Free Survival
Cause of Death
Therapeutics
Survival Rate
Outcome Assessment (Health Care)
Lung
Liver
Neoplasms

Keywords

  • Colorectal cancer
  • Metastases
  • Oligometastases
  • SBRT
  • Stereotactic body radiation therapy
  • Systemic treatment

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Radiology Nuclear Medicine and imaging

Cite this

@article{4f41bf4ad431419685467209ad71c6fa,
title = "Predictive factors for survival of oligometastatic colorectal cancer treated with Stereotactic body radiation therapy",
abstract = "Background and purpose: Colorectal cancer (CRC) represents one of the major leading causes of death from cancer. Aim of the present study was to analyze outcome of oligometastatic CRC patients treated with stereotactic body radiation therapy (SBRT), and to evaluate predictive factors of survival. Materials and methods: We included patients with maximum 5 metastases. Previous/concomitant systemic treatments were allowed. End points of the present study were the outcome in terms of Local control of treated metastases (LC), progression free survival (PFS), and overall survival (OS). Results: 437 metastases were treated in 270 patients. Lung was site of metastases in 48.5{\%} of cases, followed by liver (36.4{\%}). Systemic treatment was administered before SBRT in 199 patients (73.7{\%}). Median follow-up time was 23 months (3–98.7). Rates of LC at 1, 3 and 5 years were 95{\%}, 73{\%} and 73{\%}, respectively. Time from diagnosis of metastases to SBRT was the only factor predictive of LC (HR 1.62, p = 0.023). Median PFS was 8.6 months. Rates of OS at 1, 3 and 5 years were 88.5{\%}, 56.6{\%}, and 37.2{\%}, respectively. Lesion greater than 30 mm (HR 1.82, p = 0.030), presence of non-lung metastases (HR 1.67, p = 0.020), the use of systemic treatment before SBRT (HR 1.82, p = 0.023), and progression of treated metastases (HR 1.80, p = 0.007), were all predictive of worse OS. Conclusions: Stereotactic body radiation therapy represents an effective approach in the management of oligometastatic CRC. Control of treated oligometastases seems to be a strong positive predictive factor for both PFS and OS.",
keywords = "Colorectal cancer, Metastases, Oligometastases, SBRT, Stereotactic body radiation therapy, Systemic treatment",
author = "Ciro Franzese and Tiziana Comito and Eno Toska and Angelo Tozzi and Elena Clerici and {De Rose}, Fiorenza and Davide Franceschini and Pierina Navarria and Giacomo Reggiori and Stefano Tomatis and Marta Scorsetti",
year = "2018",
month = "1",
day = "1",
doi = "10.1016/j.radonc.2018.10.024",
language = "English",
journal = "Radiotherapy and Oncology",
issn = "0167-8140",
publisher = "Elsevier Ireland Ltd",

}

TY - JOUR

T1 - Predictive factors for survival of oligometastatic colorectal cancer treated with Stereotactic body radiation therapy

AU - Franzese, Ciro

AU - Comito, Tiziana

AU - Toska, Eno

AU - Tozzi, Angelo

AU - Clerici, Elena

AU - De Rose, Fiorenza

AU - Franceschini, Davide

AU - Navarria, Pierina

AU - Reggiori, Giacomo

AU - Tomatis, Stefano

AU - Scorsetti, Marta

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Background and purpose: Colorectal cancer (CRC) represents one of the major leading causes of death from cancer. Aim of the present study was to analyze outcome of oligometastatic CRC patients treated with stereotactic body radiation therapy (SBRT), and to evaluate predictive factors of survival. Materials and methods: We included patients with maximum 5 metastases. Previous/concomitant systemic treatments were allowed. End points of the present study were the outcome in terms of Local control of treated metastases (LC), progression free survival (PFS), and overall survival (OS). Results: 437 metastases were treated in 270 patients. Lung was site of metastases in 48.5% of cases, followed by liver (36.4%). Systemic treatment was administered before SBRT in 199 patients (73.7%). Median follow-up time was 23 months (3–98.7). Rates of LC at 1, 3 and 5 years were 95%, 73% and 73%, respectively. Time from diagnosis of metastases to SBRT was the only factor predictive of LC (HR 1.62, p = 0.023). Median PFS was 8.6 months. Rates of OS at 1, 3 and 5 years were 88.5%, 56.6%, and 37.2%, respectively. Lesion greater than 30 mm (HR 1.82, p = 0.030), presence of non-lung metastases (HR 1.67, p = 0.020), the use of systemic treatment before SBRT (HR 1.82, p = 0.023), and progression of treated metastases (HR 1.80, p = 0.007), were all predictive of worse OS. Conclusions: Stereotactic body radiation therapy represents an effective approach in the management of oligometastatic CRC. Control of treated oligometastases seems to be a strong positive predictive factor for both PFS and OS.

AB - Background and purpose: Colorectal cancer (CRC) represents one of the major leading causes of death from cancer. Aim of the present study was to analyze outcome of oligometastatic CRC patients treated with stereotactic body radiation therapy (SBRT), and to evaluate predictive factors of survival. Materials and methods: We included patients with maximum 5 metastases. Previous/concomitant systemic treatments were allowed. End points of the present study were the outcome in terms of Local control of treated metastases (LC), progression free survival (PFS), and overall survival (OS). Results: 437 metastases were treated in 270 patients. Lung was site of metastases in 48.5% of cases, followed by liver (36.4%). Systemic treatment was administered before SBRT in 199 patients (73.7%). Median follow-up time was 23 months (3–98.7). Rates of LC at 1, 3 and 5 years were 95%, 73% and 73%, respectively. Time from diagnosis of metastases to SBRT was the only factor predictive of LC (HR 1.62, p = 0.023). Median PFS was 8.6 months. Rates of OS at 1, 3 and 5 years were 88.5%, 56.6%, and 37.2%, respectively. Lesion greater than 30 mm (HR 1.82, p = 0.030), presence of non-lung metastases (HR 1.67, p = 0.020), the use of systemic treatment before SBRT (HR 1.82, p = 0.023), and progression of treated metastases (HR 1.80, p = 0.007), were all predictive of worse OS. Conclusions: Stereotactic body radiation therapy represents an effective approach in the management of oligometastatic CRC. Control of treated oligometastases seems to be a strong positive predictive factor for both PFS and OS.

KW - Colorectal cancer

KW - Metastases

KW - Oligometastases

KW - SBRT

KW - Stereotactic body radiation therapy

KW - Systemic treatment

UR - http://www.scopus.com/inward/record.url?scp=85055981657&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85055981657&partnerID=8YFLogxK

U2 - 10.1016/j.radonc.2018.10.024

DO - 10.1016/j.radonc.2018.10.024

M3 - Article

AN - SCOPUS:85055981657

JO - Radiotherapy and Oncology

JF - Radiotherapy and Oncology

SN - 0167-8140

ER -